McGill University Health Centre
Montréal, QC
Filters
Save & Share
Clear Filters
Diagnosis
Treatment History
BCMA Therapy
This stands for B Cell Maturation Antigen (BCMA) and includes treatments such as ide-cel, cilta-cel or belantamab mafodotin.
Accepting patients
QUINTESSENTIAL
Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
Learn more- CAR T Cell
- GPRC5D
- Phase 2
Not yet accepting
CARTITUDE-6
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)
Learn more- Autologous Stem Cell Transplant
- CAR T Cell
- BCMA
- Phase 3
Accepting patients
AZD0305
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
Learn more- Antibody Drug Conjugate (ADC)
- GPRC5D
- Phase 1/2